Richard Delmar Hall
Associate Professor of Medicine, Medicine- Hematology and Oncology
1240 Lee St.
Charlottesville, VA 22903
Bio & Overview
Academic Information
- Department
- Medicine- Hematology and Oncology
Primary Education
- Chief Resident, University of Virginianull
- Clinical Fellowship, Hematology-Oncology, H. Lee Moffitt Cancer Center and Research Institutenull
- MD, University of Texas Southwestern Medical Centernull
- MS, Clinical & Translational Research, University of South Floridanull
- Residency, University of Virginianull
Research Interests
Selected Publications
2022
Shantzer, L. B., Dougherty, S. C., Bolte, F., Melson, J. W., Reed, D. R., Lynch, A. C., . . . Hall, R. D. (2022). Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report. CLINICAL LUNG CANCER, 24(2), e60-e64. doi:10.1016/j.cllc.2022.11.006
Morris, B. B., Smith, J. P., Zhang, Q., Jiang, Z., Hampton, O. A., Churchman, M. L., . . . Mayo, M. W. (2022). Replicative Instability Drives Cancer Progression. BIOMOLECULES, 12(11). doi:10.3390/biom12111570
Bolte, F. J. J., McTavish, S., Wakefield, N., Shantzer, L., Hubbard, C., Krishnaraj, A., . . . Hall, R. D. D. (2022). Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.986236
2021
Dougherty, S. C., Lynch, A. C., & Hall, R. D. (2021). Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use. CLINICAL CASE REPORTS, 9(6). doi:10.1002/ccr3.4227
2020
Hollen, P. J., Gralla, R. J., Gentzler, R. D., Hall, R. D., Coyne, B., Cheng, H., . . . Lesser, M. (2021). Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. ONCOLOGIST, 26(3), 224-230. doi:10.1002/onco.13571
Dutta, S. W., Mack, M. L., Aliotta, E., Ward, K. A., Muller, D. A., Larner, J. M., . . . Sheehan, J. P. (2020). Intracranial disease control forEGFR-mutant andALK-rearranged lung cancer with large volume or symptomatic brain metastases. JOURNAL OF NEURO-ONCOLOGY, 149(2), 357-366. doi:10.1007/s11060-020-03615-4
Morris, B. B., Wages, N. A., Grant, P. A., Stukenberg, P. T., Gentzler, R. D., Hall, R. D., . . . Mayo, M. W. (2021). MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. FRONTIERS IN ONCOLOGY, 10. doi:10.3389/fonc.2020.585551
2019
McLoughlin, E. M., Fadul, C. E., Patel, S. H., Hall, R. D., & Gentzler, R. D. (2019). Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma. JOURNAL OF THORACIC ONCOLOGY, 14(12), E269-E271. doi:10.1016/j.jtho.2019.07.019
Reed, D. R., Hall, R. D., Gentzler, R. D., Volodin, L., Douvas, M. G., & Portell, C. A. (2019). Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(6), E247-E250. doi:10.1016/j.clml.2019.03.001
2018
Volaric, A., Gentzler, R., Hall, R., Mehaffey, J. H., Stelow, E. B., Bullock, T. N., . . . Mills, A. M. (2018). Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 42(9), 1216-1223. doi:10.1097/PAS.0000000000001099
Zaemes, J., Hall, R. D., & Gentzler, R. D. (2018). Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations. JOURNAL OF THORACIC ONCOLOGY, 13(8), E136-E137. doi:10.1016/j.jtho.2018.03.021
2017
Gentzler, R. D., Mohindra, N. A., Hanna, N., Chae, Y. K., Jalal, S. I., Hall, R., . . . Patel, J. D. (2017). Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(1), 236. doi:10.1016/j.ijrobp.2017.01.161
Devitt, M., Hall, R., & Gentzler, R. D. (2017). Peripheral Blood Cell Free DNA to Monitor Mutational Response in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(1), 250. doi:10.1016/j.ijrobp.2017.01.197
2016
Gentzler, R., Hall, R., Kunk, P. R., Gaughan, E., Dillon, P., Slingluff, C. L. J., & Rahma, O. E. (2016). Beyond melanoma: inhibiting the PD-1/PDL-1 pathway in solid tumors. IMMUNOTHERAPY, 8(5), 583-600. doi:10.2217/imt-2015-0029
Yang, J. C. -H., Popat, S., Novello, S., Groen, H. J. M., Perol, M., Felip, E., . . . Wakelee, H. A. (2016). TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.. JOURNAL OF CLINICAL ONCOLOGY, 34(15). doi:10.1200/JCO.2016.34.15_suppl.TPS9106
2015
Hall, R. D., Le, T. M., Haggstrom, D. E., & Gentzler, R. D. (2015). Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). TRANSLATIONAL LUNG CANCER RESEARCH, 4(5), 515-523. doi:10.3978/j.issn.2218-6751.2015.06.09
Smith, M. A., Hall, R., Fisher, K., Haake, S. M., Khalil, F., Schabath, M. B., . . . Haura, E. B. (2015). Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.. Science signaling, 8(359), ra4. doi:10.1126/scisignal.2005906
2014
Hall, R. D., & Kudchadkar, R. R. (2014). BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies. CANCER CONTROL, 21(3), 221-230. doi:10.1177/107327481402100307
2013
Hall, R. D., Gray, J. E., & Chiappori, A. A. (2013). Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer control : journal of the Moffitt Cancer Center, 20(1), 22-31. doi:10.1177/107327481302000105